New Guidance for Improving Parenteral Nutrition Safety and Patient Outcomes (CE/CME Webcast)
Activity Description and Purpose
Parenteral nutrition (PN), a high-alert medication, is used for numerous indications. This webcast, based on the proceedings of a symposium, provides the latest practical approaches to optimize PN and injectable lipid emulsions in adult home and hospital patients. The faculty will also review the recent ASPEN guidance for PN filtration. Cases are used to enhance the learning experience.
This educational activity is intended for dietitians, pharmacists, nurses, and physicians engaged in the care of patients requiring parenteral nutrition.
After completing this activity, participants will be better able to:
- Identify dosing of various lipid injectable emulsions to prevent essential fatty acid deficiency
- Demonstrate appropriate use of lipid injectable emulsion in hospital and home adult patients
- Recognize factors that increase risk for complications related to parenteral nutrition and lipid injectable emulsion solutions
- Recommend guideline-based filtering for parenteral nutrition and lipid injectable emulsion solutions
Phil Ayers, PharmD, BCNSP, FASHP (Chair)
Clinical Associate Professor
Chief of Clinical Pharmacy Services
School of Pharmacy
University of Mississippi
Vanessa Kumpf, PharmD, BCNSP, FASPEN
Clinical Pharmacist Specialist
Center for Human Nutrition
Vanderbilt University Medical Center
Jay M. Mirtallo, MS, RPh, BCNSP, FASHP
Clinical Practice Specialist
The American Society for Parenteral and Enteral Nutrition
The Ohio State University College of Pharmacy
Kris Mogensen, MS, RD-AP, LDN, CNSC
Team Leader Dietitian Specialist
Department of Nutrition
Brigham and Women’s Hospital
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Phil Ayers, PharmD, BCNSP, is a consultant for Fresenius Kabi USA; and is on the speakers bureau for Fresenius Kabi USA.
Vanessa Kumpf, PharmD, BCNSP, is a consultant for American Regent, Inc, Fresenius Kabi USA, and Takeda Pharmaceuticals USA, Inc.
Jay M. Mirtallo, MS, RPh, BCNSP, is a consultant for Fresenius Kabi USA; and is on the speakers bureau for Fresenius Kabi USA.
Kris Mogensen, MS, RD-AP, LDN, CNSC, is an advisory board member of Baxter.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Dietitians (CDR) Credit Designation
Amedco LLC designates this activity for a maximum of 1.5 CPEUs.
For Pharmacists and Nurses
Interprofessional Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 1.5 knowledge-based CPE contact hours.
The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Fresenius Kabi USA.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco LLC, or Fresenius Kabi USA.
©2022 MedEdicus LLC. 267.2
- 1.50 ACPE
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDR
- 1.50 Participation